Neogen (NEOG) Second Quarter Earnings Report Preview: Key Points to Watch

Neogen, a leading life sciences company trading on the NASDAQ under the ticker NEOG, is gearing up to release its second-quarter earnings report this week. Last quarter, Neogen fell short of revenue expectations by 1.5%, posting revenues of $221 million, marking a 3.4% decline compared to the previous year. The company also disappointed with a significant miss on earnings per share estimates and full-year EBITDA guidance, failing to meet analysts’ expectations.

As the upcoming earnings report approaches, analysts are projecting a further 6% decline in revenue year on year for Neogen, with expectations set at $222.5 million. This would continue the deceleration trend from the 2.1% decrease seen in the same quarter last year. Adjusted earnings are anticipated to be around $0.09 per share for the quarter.

Despite the challenges Neogen faced in the previous quarter, analysts have maintained their estimates over the last month, indicating a sense of stability leading up to the earnings announcement. It’s worth noting that Neogen has fallen short of Wall Street’s revenue estimates five times in the past two years, highlighting the company’s struggle to meet expectations consistently.

Looking at Neogen’s peers in the healthcare equipment and supplies sector, some companies have already reported their second-quarter results, offering insights into the industry’s performance. Boston Scientific, for example, saw a 22.8% increase in revenue year on year, surpassing analysts’ expectations by 3.4%. On the other hand, Abbott Laboratories reported a 7.4% revenue growth, outperforming estimates by 0.9%. Following these results, Boston Scientific’s stock rose by 2.9%, while Abbott Laboratories experienced a 6.1% decline in share price.

Leading up to the earnings announcement, investors in the healthcare equipment and supplies segment have remained steady, with stock prices holding relatively flat over the past month. In contrast, Neogen’s stock has seen a 5.8% increase during the same period, with an average analyst price target of $7.50, higher than the current share price of $5.06.

Share buybacks can be a strategic move for companies with excess cash, potentially boosting shareholder value. Neogen’s upcoming earnings report will shed light on the company’s financial performance and strategic decisions. Stay tuned for the latest updates on Neogen’s second-quarter earnings to assess whether it presents a buying opportunity or signals a cautionary stance for investors in the healthcare equipment and supplies sector.